Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 1

2(28.6%)

Phase 2

2(28.6%)

7Total

Phase 3(3)

Phase 1(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06419374Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Role: lead

NCT06318169Phase 3Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Role: lead

NCT04929483Phase 2Completed

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Role: lead

NCT05852431Phase 3Active Not Recruiting

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Role: lead

NCT04541186Phase 2Completed

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Role: lead

NCT04048135Phase 1Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Role: lead

NCT05022693Phase 1Completed

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

Role: lead

All 7 trials loaded